ACRO Biomedical Q2 net loss widens to $21,356; operating expenses rise to $17,554

• ACRO Biomedical posted a net loss of $21,356 for the quarter ended June 30, 2026, widening from $15,562.
• Operating expenses climbed to $17,554 from $13,614, mainly on general and administrative costs and public-company professional fees.
• Interest expense to two minority stockholders rose to $3,802 from $1,948; the company reported no revenue.
• Cash was $3,648 at June 30, 2026, while working capital deficit widened to $444,789 from $386,964 at Dec. 31, 2025.
• Management said it had no sales since Dec. 31, 2022, and continues to rely on minority-stockholder advances for funding.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ACRO Biomedical Co. Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001640334-26-001345), on August 14, 2026, and is solely responsible for the information contained therein.